TR199902865T2 - Fizyolojiksel ortamda düsük çözünürlüge sahip peptidlerin farmakolojik kompozisyonlari. - Google Patents

Fizyolojiksel ortamda düsük çözünürlüge sahip peptidlerin farmakolojik kompozisyonlari.

Info

Publication number
TR199902865T2
TR199902865T2 TR1999/02865T TR9902865T TR199902865T2 TR 199902865 T2 TR199902865 T2 TR 199902865T2 TR 1999/02865 T TR1999/02865 T TR 1999/02865T TR 9902865 T TR9902865 T TR 9902865T TR 199902865 T2 TR199902865 T2 TR 199902865T2
Authority
TR
Turkey
Prior art keywords
peptides
resolution
low
pharmacological compositions
physiological setting
Prior art date
Application number
TR1999/02865T
Other languages
English (en)
Inventor
Richardson Peter
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of TR199902865T2 publication Critical patent/TR199902865T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mevcut bulus a) aktif içerik olarak, sulu fizyolojiksel salin çözelti içersinde zayif çözünürlüge sahip bir peptid, b) bir iyonik olmayan hidrotropik, farmakolojik olarak kabul edilebilen ajan ve c) bir fizyolojiksel sulu çözelti içeren farmakolojik kompozisyonlar ile ilgilidir.
TR1999/02865T 1997-05-28 1998-05-26 Fizyolojiksel ortamda düsük çözünürlüge sahip peptidlerin farmakolojik kompozisyonlari. TR199902865T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
TR199902865T2 true TR199902865T2 (tr) 2000-05-22

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02865T TR199902865T2 (tr) 1997-05-28 1998-05-26 Fizyolojiksel ortamda düsük çözünürlüge sahip peptidlerin farmakolojik kompozisyonlari.

Country Status (27)

Country Link
US (1) US6331520B1 (tr)
EP (2) EP0880969A1 (tr)
JP (1) JP2002502384A (tr)
KR (1) KR100552546B1 (tr)
CN (1) CN1159062C (tr)
AR (1) AR012868A1 (tr)
AT (1) ATE252909T1 (tr)
AU (1) AU743152B2 (tr)
BG (1) BG64668B1 (tr)
BR (1) BR9809708A (tr)
CA (1) CA2291765A1 (tr)
CZ (1) CZ298825B6 (tr)
DE (1) DE69819322T2 (tr)
DK (1) DK0984788T3 (tr)
EA (1) EA002227B1 (tr)
EE (1) EE04001B1 (tr)
ES (1) ES2210772T3 (tr)
HK (1) HK1029928A1 (tr)
IL (2) IL133176A0 (tr)
NO (1) NO323697B1 (tr)
NZ (1) NZ500777A (tr)
PL (1) PL192647B1 (tr)
PT (1) PT984788E (tr)
SI (1) SI0984788T1 (tr)
SK (1) SK284640B6 (tr)
TR (1) TR199902865T2 (tr)
WO (1) WO1998053844A1 (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
WO2008122118A1 (en) * 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
WO2014059228A1 (en) * 2012-10-12 2014-04-17 L'oreal Cosmetic compositions containing at least one hydrotrope and at least one active compound
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9669242B2 (en) * 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
AU2017220728A1 (en) 2016-02-16 2018-08-23 Strongbridge Dublin Limited Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, SST-R5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
JP3122128B2 (ja) * 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
CA2103163C (en) * 1991-08-26 1998-10-20 Mou-Ying Fu Lu Compositions and methods for the sublingual or buccal administration of therapeutic agents
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
TW280770B (tr) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
JP2002502384A (ja) 2002-01-22
EE9900545A (et) 2000-06-15
ATE252909T1 (de) 2003-11-15
EP0984788A1 (en) 2000-03-15
CA2291765A1 (en) 1998-12-03
KR100552546B1 (ko) 2006-02-14
DK0984788T3 (da) 2004-03-08
EP0984788B1 (en) 2003-10-29
DE69819322D1 (de) 2003-12-04
BG103884A (en) 2000-07-31
CZ298825B6 (cs) 2008-02-20
AU8106298A (en) 1998-12-30
SK284640B6 (sk) 2005-08-04
WO1998053844A1 (en) 1998-12-03
NO995763L (no) 1999-11-24
CN1263469A (zh) 2000-08-16
EE04001B1 (et) 2003-04-15
BG64668B1 (bg) 2005-11-30
PT984788E (pt) 2004-01-30
BR9809708A (pt) 2000-07-11
PL192647B1 (pl) 2006-11-30
US6331520B1 (en) 2001-12-18
CN1159062C (zh) 2004-07-28
SK159799A3 (en) 2000-07-11
EA199901089A1 (ru) 2000-06-26
ES2210772T3 (es) 2004-07-01
EA002227B1 (ru) 2002-02-28
PL336982A1 (en) 2000-07-31
NO995763D0 (no) 1999-11-24
NZ500777A (en) 2001-09-28
CZ423199A3 (cs) 2000-05-17
HK1029928A1 (en) 2001-04-20
AU743152B2 (en) 2002-01-17
AR012868A1 (es) 2000-11-22
IL133176A0 (en) 2001-03-19
DE69819322T2 (de) 2004-07-29
IL133176A (en) 2006-08-01
EP0880969A1 (en) 1998-12-02
NO323697B1 (no) 2007-06-25
SI0984788T1 (en) 2004-02-29
KR20010012253A (ko) 2001-02-15

Similar Documents

Publication Publication Date Title
TR199902865T2 (tr) Fizyolojiksel ortamda düsük çözünürlüge sahip peptidlerin farmakolojik kompozisyonlari.
PT1105409E (pt) Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
TW200626613A (en) Analogues of GLP-1
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
MY129356A (en) Electrospun pharmaceutical compositions
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
BR0314354A (pt) Formação para gentes lipofìlicos
NZ287857A (en) Delivery of water insoluble active agents using tocopherol as emulsifier or solvent
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
PT991407E (pt) Estabilizacao de benzimidazoles sensiveis a acidos com combinacoes de amino/ciclodextrinas
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
TR200202466T2 (tr) Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar.
BR0009678A (pt) Compostos, composição farmacêutica, e, uso de compostos
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
KR960702754A (ko) 생리적으로 활성인 펩티드를 함유하는 질내 투여 제제(vaginal preparation containing physiologically active peptide)
CO5050337A1 (es) Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma
BR9714279A (pt) Preparação aquosa, e, uso da mesma.
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma
AU3739500A (en) Protease resistant flint analogs
ATE491719T1 (de) Peptidinhibitoren gegen den eintritt von hiv in zellen
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen